Cancer News

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer (07/23/2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. The FDA also approved Kisqali in combination with fulvestrant for the …

Continue reading "FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer"

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients (07/09/2018)

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American …

Continue reading "Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients"

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation (06/21/2018)

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy in patients with inherited BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. About Talazoparib Talazoparib is an investigational anti-cancer …

Continue reading "U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation"

Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer (04/19/2018)

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant differences in effectiveness or safety, For the study, 3697 postsurgical patients with invasive hormone receptor–positive breast cancer were enrolled from 76 Italian public healthcare institutions between March 9, …

Continue reading "Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer"

FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer (03/26/2018)

CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant treatment of patients with HER2-positive early stage breast cancer at high risk of recurrence. About Perjeta Breast cancer is the second leading cause of cancer-related death among …

Continue reading "FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer"

At-home Genetic Testing may be Convenient, but it isn’t Complete (03/20/2018)

March 14, 2018 https://www.statnews.com/2018/03/14/genetic-testing-23andme-brca/   Home delivery for everything from fresh produce to custom-selected clothing has become a way of life for many Americans. While most home-delivery conveniences are generally changing our lives for the better — giving us more time and choices — at-home genetics kits that reveal information about the risk of developing …

Continue reading "At-home Genetic Testing may be Convenient, but it isn’t Complete"

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer (03/12/2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. About VerzenioTM Verzenio is an inhibitor of cyclin-dependent kinases …

Continue reading "FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer"

Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer (02/21/2018)

A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC), according to new research published by a multi-institutional team of researchers.1,2 Although TNBC represents just 10-15 percent of all breast diagnoses, the disease is responsible for 35 …

Continue reading "Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer"

Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer (02/13/2018)

CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. Results from …

Continue reading "Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer"

Five Common Sign & Symptoms of Breast Cancer (02/12/2018)

CancerConnect News: Breast cancer is a cancer that originates in the area of the breast, where cells replicate too quickly, causing a tumor. Breast cancer is most common in women, but I can also occur in men. Breast cancer is caused by an abnormality that is genetic, but only a very low percentage of such …

Continue reading "Five Common Sign & Symptoms of Breast Cancer"